Your browser doesn't support javascript.
loading
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.
Pohlen, Michele; Marx, Julia; Mellmann, Alexander; Becker, Karsten; Mesters, Rolf M; Mikesch, Jan-Henrik; Schliemann, Christoph; Lenz, Georg; Müller-Tidow, Carsten; Büchner, Thomas; Krug, Utz; Stelljes, Matthias; Karch, Helge; Peters, Georg; Gerth, Hans U; Görlich, Dennis; Berdel, Wolfgang E.
Afiliação
  • Pohlen M; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany michele.pohlen@ukmuenster.de.
  • Marx J; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany.
  • Mellmann A; Institute of Hygiene, University Hospital Muenster, Germany.
  • Becker K; Institute of Medical Microbiology, University Hospital Muenster, Germany.
  • Mesters RM; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany.
  • Mikesch JH; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany.
  • Schliemann C; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany.
  • Lenz G; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany Translational Oncology, University Hospital Muenster, Germany Cluster of Excellence EXC 1003, Cells in Motion, Germany.
  • Müller-Tidow C; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany Department of Medicine IV, Hematology and Oncology, University Hospital Halle, Germany.
  • Büchner T; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany.
  • Krug U; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany Department of Medicine 3, Klinikum Leverkusen, Germany.
  • Stelljes M; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany.
  • Karch H; Institute of Hygiene, University Hospital Muenster, Germany Cluster of Excellence EXC 1003, Cells in Motion, Germany.
  • Peters G; Institute of Medical Microbiology, University Hospital Muenster, Germany Cluster of Excellence EXC 1003, Cells in Motion, Germany.
  • Gerth HU; Department of Medicine D, Nephrology and Rheumatology, University Hospital Muenster, Germany.
  • Görlich D; Institute of Biostatistics and Clinical Research, University Muenster, Germany.
  • Berdel WE; Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Germany Cluster of Excellence EXC 1003, Cells in Motion, Germany.
Haematologica ; 101(10): 1208-1215, 2016 10.
Article em En | MEDLINE | ID: mdl-27470601
ABSTRACT
Patients undergoing intensive chemotherapy for acute myeloid leukemia are at high risk for bacterial infections during therapy-related neutropenia. However, the use of specific antibiotic regimens for prophylaxis in afebrile neutropenic acute myeloid leukemia patients is controversial. We report a retrospective evaluation of 172 acute myeloid leukemia patients who received 322 courses of myelosuppressive chemotherapy and had an expected duration of neutropenia of more than seven days. The patients were allocated to antibiotic prophylaxis groups and treated with colistin or ciprofloxacin through 2 different hematologic services at our hospital, as available. The infection rate was reduced from 88.6% to 74.2% through antibiotic prophylaxis (vs without prophylaxis; P=0.04). A comparison of both antibiotic drugs revealed a trend towards fewer infections associated with ciprofloxacin prophylaxis (69.2% vs 79.5% in the colistin group; P=0.07), as determined by univariate analysis. This result was confirmed through multivariate analysis (OR 0.475, 95%CI 0.236-0.958; P=0.041). The prophylactic agents did not differ with regard to the microbiological findings (P=0.6, not significant). Of note, the use of ciprofloxacin was significantly associated with an increased rate of infections with pathogens that are resistant to the antibiotic used for prophylaxis (79.5% vs 9.5% in the colistin group; P<0.0001). The risk factors for higher infection rates were the presence of a central venous catheter (P<0.0001), mucositis grade III/IV (P=0.0039), and induction/relapse courses (vs consolidation; P<0.0001). In conclusion, ciprofloxacin prophylaxis appears to be of particular benefit during induction and relapse chemotherapy for acute myeloid leukemia. To prevent and control drug resistance, it may be safely replaced by colistin during consolidation cycles of acute myeloid leukemia therapy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Ciprofloxacina / Colistina / Antibioticoprofilaxia / Neutropenia Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Ciprofloxacina / Colistina / Antibioticoprofilaxia / Neutropenia Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha